Start here if you're new
what it is
Omeros is a clinical-stage biotech trying to turn immune-system drug research into approved medicines.
how it gets paid
Last year Omeros made n/a in revenue.
what just happened
The latest quarter showed an EPS loss of -$1.47, and the revenue base still looks essentially absent.
At a glance
C+ balance sheet — struggling to keep the lights on
80/100 earnings predictability — you can trust these numbers
-$3.14 fy2024 eps est
$74M fy2020 rev est
1.9 beta
xvary composite: 37/100 — weak
What they do
Omeros is a clinical-stage biotech trying to turn immune-system drug research into approved medicines.
The edge here is the science stack, not current sales. Omeros has 202 employees focused on complement biology (part of your immune system), so your bet is on specialized research depth. If its MASP-2 and MASP-3 programs work, one platform can support multiple drug shots.
How they make money
n/a
annual revenue
The products that matter
approved commercial therapy
YARTEMLEA (narsoplimab)
$36,000 per dose
It is the only commercial asset in the story. At $36,000 per dose, pricing power is obvious. Demand durability is the harder question.
only revenue-ready asset
preclinical pipeline candidate
OMS405 (PPARγ agonist)
$0 revenue today
This is pipeline optionality, not a business line. Right now it contributes $0 in revenue and asks investors to underwrite more development time.
option value
Key numbers
$321M
long-term debt
Debt is real cash that must be dealt with. Omeros has it without a meaningful revenue base.
$3.14
2024 EPS
Loss per share tells you the company is still burning value while waiting for pipeline outcomes.
1.9
beta
Beta measures volatility → bigger stock swings than the market → you need a strong stomach.
202
employees
This is a small team trying to carry a large clinical and financing burden.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $321M (29% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for OMER right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter showed an EPS loss of -$1.47, and the revenue base still looks essentially absent.
Quarterly EPS history worsened from a -$0.63 fourth quarter in 2023 to a -$0.63 fourth quarter in 2024 after a much deeper -$1.12 second quarter in 2024. This is still a pipeline story, not an operating execution story.
$0M
revenue
-$1.47
eps
0.0%
gross margin
the number that mattered
The key number is the -$1.47 EPS loss because losses, not sales, are still defining the business.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is YARTEMLEA commercialization failing to outrun the cash burn. This is not a diversified drug portfolio. It is one commercial asset carrying a company that lost $121.2M on $74M of revenue.
med
Cash burn stays bigger than the business
A trailing net loss of $121.2M against $74M in annual revenue means operations are not paying for themselves. A -253% operating margin makes that point in permanent marker.
If that gap does not narrow, outside capital keeps doing the heavy lifting.
med
The story leans on one approved asset
YARTEMLEA is the only commercial asset, priced at $36,000 per dose. OMS405 and the rest of the pipeline contribute $0 in current revenue.
If adoption disappoints or access gets harder, there is no second engine ready to step in.
med
The calendar matters almost as much as the science
The pending EMA decision for YARTEMLEA by May 1, 2026 and an ongoing civil antitrust lawsuit keep this story tied to external outcomes management does not fully control.
A delay or adverse outcome would leave investors with the same burn, the same debt, and fewer paths to scale.
A $793M company with $321M in long-term debt lost $121.2M last year on $74M of revenue. That is a narrow margin for error.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
March 30, 2026 earnings report
Consensus expects a loss of $0.58 per share on $0 revenue. You are looking for cash-runway language more than headline sales.
regulatory
EMA decision for YARTEMLEA
Scheduled for May 1, 2026. European approval matters because one approved asset needs every realistic route to expansion.
metric
Losses versus revenue
The current score is $121.2M of net loss against $74M of revenue. If that spread is not improving, the thesis is not de-risking.
trend
Stock volatility stays extreme
A 52-week range of $3–$18 and a 1.9 beta tell you sentiment can swing faster than fundamentals update.
Analyst rankings
earnings predictability
80 / 100
In human-speak: the losses are fairly consistent. That does not make them good. It makes them easier to model.
beta
1.9
Beta measures how much a stock moves relative to the market. At 1.9, you should expect sharper swings than the index.
risk rank
5
A risk rank of 5 means this screens riskier than 95% of stocks. Welcome to small-cap biotech.
source: institutional data
Institutional activity
institutional ownership data for OMER is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$9
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive